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ABSTRACT. Cytokine regulation may be an important factor in the susceptibility for the development of chronic
pancreatitis; transforming growth factor-b1 (TGF-b1) plays a central role in the pathogenesis of pancreatic
fibrogenesis. The aim of our study was to analyse the relevance of TGF-b1, interleukin-8 (IL-8) and tumor necrosis
factor-a (TNF-a) polymorphisms in patients with chronic pancreatitis.Patients: of the 83 patients enrolled in the
study, 43 were treated medically and 40 patients underwent surgical intervention. Healthy blood donors (n = 75)
served as controls.Methods: the polymorphisms of TGF-b1 +869 T→ C and IL-8 -251 T→A were determined by
the ARMS method, while that of TNF-a -308 was investigated using NcoI RFLP.Results: there was a higher fre-
quency (50%) of the TT genotype of TGF-b1 +869, with a concomitantly higher TGF-b1 level in the plasma
(5.2 ± 1.7 ng/mL) of patients with chronic pancreatitis than in healthy blood donors (28% and 2.8 ± 0.9 ng/mL
respectively). The number of TT homozygotes differed significantly between the patients who underwent surgical
intervention and the controls, and even between the surgical and the non-surgical patients. The frequency of the
T/A genotype with higher IL-8 production, was significantly higher in both groups of patients than in the controls
(58% and 58% versus 40%). No correlation was found between the TNF-a -308 polymorphism and chronic
pancreatitis.Conclusions: correlations of the TGF-b1 and IL-8 single nucleotide polymorphisms (SNPs) with
chronic pancreatitis underline the importance of these cytokines in the pathomechanism of the disease. Moreover,
it seems that the TT genotype of +869 TGF-b1 might be a risk factor for the development of a severe form of
chronic pancreatitis, and could serve as a prognostic sign for any future surgical intervention or even repeat
surgery. Further studies on a larger group of patients, in addition to a follow-up study, are necessary to confirm
this preliminary observation.
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Chronic pancreatitis (CP) is characterized by dysplastic
ducts, foci of proliferating ductal cells, acinar cell degen-
eration, and fibrosis. There are a number of underlying
conditions that can contribute to an increased incidence of
CP. They include, but are not limited to, an excessive
ethanol intake, pancreatic stone formation, and recurrent
episodes of acute pancreatitis [1].
In the course of chronic pancreatitis, the pancreatic acinar
and ductal cells undergo continuous destruction and are
replaced by fibrous tissue. An overproduction of extracel-
lular matrix molecules may further compromise the re-
maining parenchyma leading to an ongoing process of
tissue destruction, which finally results in an exocrine, and
sometimes endocrine insufficiency. Recent studies have
furnished evidence of an overproduction of various growth
factors, or members of the transforming growth factor-b
family [2-4]. The overproduction of TGF-b in chronic
pancreatitis in particular, appears to be an important factor
in the production of extracellular matrix molecules, induc-
ing the connective tissue growth factor (CTGF) and sub-
sequently leading to the production of collagen, fibronec-
tin and proteoglycan.
The cytokine TGF-b1, which plays a central role in the
pathogenesis of pancreatic fibrogenesis, not only exerts
immunomodulatory functions but is also a potent fibro-
genic mediator, promoting the proliferation of fibroblasts
and the production of connective tissue. TGF-b is likely to
be involved in the fibrogenetic processes occurring in
chronic pancreatitis, thereby contributing to the loss of
functional, exocrine pancreatic tissue [5]. An upregulated
expression of TGF-b in mononuclear and ductal epithelial
cells has been observed in tissue sections from patients
with chronic pancreatitis [6].
The inflammatory processes that characterize chronic pan-
creatitis are regulated by a variety of other cytokines,
including tumor necrosis factor-alpha (TNF-a), and alsodoi
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by chemokines [7]. Thus, chemokines of the C-X-C fam-
ily, such as interleukin-8 (IL-8), and the C-C-chemokine
family, such as MCP-1, can be identified in chronic pan-
creatitis [8, 9].
The regulation of cytokines may be important with regard
to susceptibility to the development of chronic pancreati-
tis. Recent work has demonstrated a high degree of poly-
morphism in the cytokine genes involved in inflammation
and immunity [10].
The production of TGF-b1 varies from individual to indi-
vidual, and depends, in part, on the polymorphisms of this
gene. The human gene encoding TGF-b1 is located on
chromosome 19q13. A number of polymorphisms have
been described in the TGF-b1 gene, including a T-to-C
transition at nucleotide 29 at position +869, in the region
encoding the signal sequence, which results in a leucine-
proline substitution at the 10th amino acid. It has been
demonstrated that TT homozygous genotypes are high
TGF-b1 producers [11-13].
It has been reported that a T-A mutation in the -251
promoter region is accompanied by increased IL-8 produc-
tion [14]. The G-to-A transition at position -308 in the
promoter region is associated and with an elevated expres-
sion of TNF-a [15, 16].
There are conflicting results concerning the association
between TNF-a and TGF-b1 polymorphisms and chronic
pancreatitis [17-19].
We have therefore investigated this in a Central-East Euro-
pean (Hungarian) population, in addition to an investiga-
tion of IL-8 polymorphisms in order to determine whether
polymorphisms of the TGF-b1 gene at position + 869
(codon 10), the TNF-a gene at position -308, and the IL-8
gene at -251 position are associated with chronic pancre-
atitis.
PATIENTS AND METHODS
Patients
Our study involved 83 patients (24 females and 59 males;
mean age 52.7 years, range 22-70), who underwent medi-
cal or surgical treatment for chronic pancreatitis at the
Department of Internal Medicine and/or Department of
Surgery of the University of Szeged, between 2003 and
2006. The diagnosis of chronic pancreatitis was based on
the typical history (daily alcohol intake), abdominal com-
plaints (pain, bloating, steatorrhoea, etc.) and characteris-
tic morphological and/or functional alterations of the pan-
creas. The morphological changes due to chronic
inflammation of the pancreas (pancreatic calcification on
ultrasonography (US) and/or computed tomography (CT),
mild to moderate or marked ductal lesions during endo-
scopic retrograde cholangio-pancreatography- (ERCP)
examination) were assessed in each case. Pancreatic calci-
fications were found in 31 (37.5%) patients on US or CT.
According to the etiology, 65 of the patients (78.6%) had a
history of alcohol abuse (consumption of > 50 g/day) and
12 (21.4%) patients has idiopathic CP. Exocrine pancreatic
insufficiency was assessed by means of a stool elastase test
[20]. Forty seven patients with stool elastase values of less
than 200 lg were considered to have pancreatic insuffi-
ciency.
The endocrine function was evaluated in non-diabetic pa-
tients by means of the oral glucose tolerance test (OGTT).
Fifty six patients (67.9%) had impaired endocrine function
(latent or manifest diabetes).
Surgical intervention
The indications for surgery were intractable pain, loss of
body weight, and obstruction of the ductal system (pancre-
atic duct, common bile duct or the duodenum) caused by
an inflammatory enlargement of the pancreatic head.
These are generally accepted indications for surgery [21-
23]. Duodenum-preserving, pancreatic head resection [24]
was performed in eight cases, organ-preserving, pancreatic
head resection [25] in 15 cases, pylorus-preserving, pan-
creatic head resection in four cases, and Wirsungo-
jejunostomy in 13 cases. Rehospitalization and repeat sur-
gery was necessary in eight cases.
The control group consisted of 75, age- and gender-
matched, healthy blood donors, who had no gastrointesti-
nal or liver diseases, and who were selected locally from
consecutive blood donors in Szeged, Hungary. The study
protocol was approved by the Ethics and Science Commit-
tee of the Ministry of Health and the University of Szeged
Regional and Institutional Committee of Science and Re-
search Ethics.
All participating subjects were of Hungarian ethnic origin
and resident in Hungary.
DNA extraction
For the study of TNF-a , TGF-b1 and IL-8 polymor-
phisms, genomic DNA purified from peripheral blood was
used. Leukocyte DNA was isolated using the High Pure
PCR Template Preparation Kit according to the manufac-
turer’s instructions (Roche Diagnostic GmbH, Mannheim,
Germany) and the genomic DNA was stored at -20°C until
further use.
Determination of TGF-b1 +869 T→C polymorphism
The defined, single-nucleotide polymorphism T29-C in
exon 1 of the human TGF-b1 gene was determined with an
amplification refractory mutation system -ARMS- [26],
using a generic primer (sense), (5’-TCCGTGGGA-
TACTGAGACACC-3’); and with two allele-specific anti-
sense primers, differing from each other in only one base at
the 3’-end- primer C: 5’-GCAGCGGTAGCAGCA-
GCG-3’ and primer T: 5’-AGCAGCGGTAGCAGC-
AGCA-3’. The reaction mixture of 50 ll contained 100 ng
of genomic DNA, 20 pmol each of the sense and the
anti-sense primer, 1.25 U Taq DNA polymerase, 1.5 mM
MgCl2, 1xPCR Taq polymerase buffer + (NH4)2SO4, and
25 mM of each dNTP (Fermentas, Vilnius, Lithuania). The
thermocycling procedure was as follows: initial denatur-
ation at 94 °C for 5 minutes; 35 cycles of 94 °C for 30
seconds, 60 °C for 30 seconds and 72 °C for 30 seconds,
and a final extension at 72 °C for 5 minutes. The PCR
products were analyzed using 1.5% agarose (Sigma-
Aldrich, St. Luis, MO, USA) gel electrophoresis, visual-
ised under UV illumination and stained with 0.4 mg/L
ethidium bromide. The expected size of the specific ampli-
fication product was 241 bp. Samples from two known
homozygous individuals and one heterozygous individual,
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confirmed by sequencing, were included in each reaction.
Sequencing was performed with an automated sequencer
(ABI Prism; Applied Biosystems, CA, USA).
Determination of IL-8 -251 polymorphisms
A single nucleotide T→A polymorphism at -251 nt, rela-
tive to the transcription start site, accompanied by in-
creased IL-8 production was typed by amplification refrac-
tory mutation system (ARMS) [14].Allele specific primers
were: 5′ CCACAATTTGGTGAATTATCAAT 3 (-251A)
and 5′ CACAATTTGGTGAATTATCAAA 3′ (-251T).
The consensus primer was: 5′ TGCCCCTTCACTCTGT-
TAAC 3′, giving a PCR product of 336bp. In each reaction,
a second set of primers for exon 3 of the HLA-DRB1 gene
(forward: 5′ TGCCAAGTGGAGCACCCAA 3′, reverse:
5′ GCATCTTGCTCTGTGCAGAT 3′, product size (796
bp) was used as a control for PCR efficiency. Reactions
were carried out using Advantage-GC cDNA polymerase
mix and buffer (Clontech, Palo Alto, CA, USA), under the
following conditions: 96 °C for 120 s; four cycles of 96 °C
for 35 s, 68 °C for 45s, 72 °C for 35s; four cycles of 96 °C
for 35 s, 65 °C for 45s, 72 °C for 45s; four cycles of 96 °C
for 35 s, 62 °C for 45s, 72 °C for 55s; ten cycles of 96 °C
for 35 s, 58 °C for 45s, 72 °C for 65s; ten cycles of 96 °C
for 35 s, 55 °C for 45s, 72 °C for 75s; four cycles of 96 °C
for 35 s, 52 °C for 45s, 72 °C for 85s; four cycles of 96 °C
for 35 s, 50 °C for 45s, 72 °C for 90s; 72°C for 5 min.
Determination of TNF-a -308 G→A polymorphism
This SNP of TNF-a at position –308 in the promoter region
was analyzed by PCR-RFLP (restriction fragment length
polymorphism) [15]. A single base change at the 3’ end of
primer A1 was required for the formation of an NcoI
(Fermentas, Vilnius, Lithuania) recognition sequence
CCATGG (instead of GCATG originally found on the gene
investigated) (primer A1:5’-AGGCAATAGGTTTTG-
AGGGCCAT-3’ and primer A2:5’-TCCTCCCTGCTC-
CGAT TCCG-3’). The reaction mixture of 100 lL con-
tained 100 ng of genomic DNA, 20 pmol each of the A1
and the A2 primer, 2.5 U Taq DNA polymerase, 1.5 mM
MgCl2, 1xPCR Taq polymerase buffer + (NH4)2SO4 (Fer-
mentas, Vilnius, Lithuania) and 25 mM of each dNTP
(Fermentas, Vilnius, Lithuania). The PCR conditions were
as follows: initial denaturation at 94 °C for 3 minutes; 36
cycles of 94 °C for 1 minute, 60 °C for 1 minute and 72 °C
for 1 minute, and a final extension at 72 °C for 5 minutes.
The amplified product was digested with the endonuclease
NcoI and analyzed on a 12% polyacrylamide gel under UV
illumination. The TNF G allele gave two fragments of
87 bp and 20 bp, while the TNF A allele gave a single,
107 bp fragment.
TGF-b ELISA
Venous blood was collected from healthy blood donors
and from patients with chronic pancreatitis into EDTA-
containing tubes for collecting plasma. Blood was col-
lected from surgical patients before the operation. Cen-
trifugation was carried out at 2000g for 10 min at 4oC. All
samples were stored at -20 oC. Plasma concentrations of
TGF-b1 were determined by enzyme-linked immunosor-
bent assay kit (R&D System Inc., Minneapolis, USA)
according to the manufacturer’s instructions.
Statistical analysis
Statistical analyses for comparison of allele and genotype
frequencies between groups were performed using the v2
test and Fisher’s exact test if one cell had n < 5. The
probability level of p < 0.05 indicated statistical signifi-
cance. The relationship between genotypes and disease
severity is presented as the odds ratio (OR), with a 95%
confidence interval (95% CI).The genotype frequencies
for each polymorphism were tested for deviation from the
Hardy-Weinberg equilibrium by means of the v2 test, with
one degree of freedom used [27]. The levels of TGF-b1 in
the plasma were compared by means of one-way ANOVA.
The Bonferroni test was used for post hoc pairwise mul-
tiple comparisons. In all tests, an a level of p< 0.05 was
taken as an indication of statistical significance. All statis-
tical calculations were performed with the GraphPad
Prism4 (GraphPad Software Inc., San Diego, CA, USA)
statistical program.
RESULTS
TGF-b1 +869 T→C polymorphism
The genotypic distributions of the +869 T→C polymor-
phism of the TGF-b1 gene are shown in table 1. The
distribution of the TGF-b1 genotypes was in accordance
with the Hardy-Weinberg equilibrium in the control popu-
lation (v2 = 2.95; p = 0.2676), but not in the patient group
with chronic pancreatitis (v2 = 5.215, p = 0.022).
Table 1
TGF-b1 +869 genotype distribution in patients with chronic pancreatitis and in control subjects
TT TC CC
Operated 25/40 (62%) 10/40 (25%) 5/40 (13%) p = 0.001a
p = 0.0007 versus controlb
Non operated 17/43 (39.5%) 17/43 (39.5%) 9/43 (20%)
p = 0.223 versus control nsb
p = 0.0486 versus operatedb
Total 42/83 (50%) 27/83 (33%) 14/83 (17%) p = 0.009a
p = 0.005 versus controlb
Control 21/75 (28%) 30/75 (40%) 24/75 (32.%)
ns = non-significant.
a chi-square test versus control.
b Fisher test.
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There was a significant difference in genotypic distribution
between the chronic pancreatic patients overall and the
healthy controls (p = 0.009, v2 = 9.409). When the pa-
tients were stratified according progression of the disease -
i.e. medical treatment or surgical treatment – a significant
difference was observed only between the controls and the
surgical patients (p = 0.0012), and not between the con-
trols and the patients receiving only medical treatment. To
elucidate the reason for this difference, we compared the
numbers of TT homozygotes among the patients and the
healthy controls. The frequency of TT homozygotes (high
TGF-b1-producing phenotype) was significantly higher in
the patient group overall (50%) than in the controls (28%)
(p = 0.005; OR = 2.634; 95% CI = 1.358-5.111). There
was an even higher freqency of the TT genotype among
patients undergoing surgical intervention as compared
with the controls , 62% versus 28%, p = 0.0007,
OR = 4.018, 95% CI = 1.796 - 8.987. There was also a
significant difference between the surgical patients, and
those treated medically (p = 0.0486, OR = 2.549,
95%CI = 1.052-6.178). Although the frequency of the TT
genotype was still higher among the patients in the medi-
cally treated (medical) group (39.5%) than in the controls,
the difference was not statistically significant.
No further significant differences were observed as regards
the SNPs when the patients were stratified according to the
presence or absence of calcification.
TGF-b1 plasma levels
Plasma levels of TGF-b1 were higher in the patients
overall than in controls (3.98 ±1.26 ng/mL versus
2.1 ± 0.85 ng/mL), and higher in the patients with the TT
genotype than in those with the CT and the CC genotypes
(5.2 ± 1.7 ng/mL versus 3.8 ± 1.1 ng/mL and versus
1.5 ± 0.5ng/mL respectively; p < 0.001 ANOVA). A simi-
lar tendency was observed in the control group; the sub-
jects with the TT genotype demonstrated the highest
plasma TGF-b1 levels (2.8 ± 0.9 ng/mL) (figure 1). How-
ever, the plasma TGF-b1 concentrations differed signifi-
cantly between the patients and the controls, both in the TT
homozygote groups and in the TC heterozygote groups.
(p < 0.001 statistically significant according the Bonfer-
roni post-test.) No significant difference was observed
between the “low-level” TGF-b1 concentrations when the
patients and controls were CC homozygotes.
IL-8 -251 polymorphism
The genotypic distribution of the –251 polymorphism of
the IL-8 gene is shown in table 2.
The distribution of IL-8 genotypes was in accordance with
the Hardy-Weinberg equilibrium both in the control popu-
lation (v2 = 2.083, p = 0.148) and in the patient group with
chronic pancreatitis (v2 = 2.413, p = 0.120).
There was a significant difference in genotype distribution
between the patients and the healthy controls
(v2 = 11.8298, p = 0.0027). There was a higher frequency
of the A/T genotype (high IL-8 producers) among those
patients with chronic pancreatitis as compared with the
controls: 48 of the 83 patients (58%) versus 30 of the 75
healthy controls (40%), p = 0.0271; OR = 2.057, 95%
CI = 1.090 – 3.882). In spite of this difference, the statis-
tical power is only 73%. Conversely, the prevalence of the
IL-8 TT, wild type genotype was significantly lower in the
group of patients (15%) than in the control group (40%)
(p = 0.007, OR = 3.590, 95% CI = 1.694-7.607).
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Figure 1
TGF-b1 plasma levels in patients with chronic pancreatitis (filled bars) and in control subjects (open bars) with different genotypes. Data are
means ±SD.
*p < 0.001 ANOVA test on patients
♦p < 0.05 ANOVA test on controls
Bonferroni post-test analysis revealed statistically significant differences between the columns, apart from between the patients and controls with
the CC genotype, and between the controls with the TC and the CC genotype.
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There was no significant difference in the genotypic distri-
bution of IL-8 polymorphism between the two groups of
patients.
TNF-a -308 G→A polymorphism
The distribution of the TNF-a -308 genotypes was in
accordance with the Hardy-Weinberg equilibrium both in
the control population (v2 = 0.0167, p = 0.897) and in the
patient group (v2 = 3.483, p = 0.062).
There were no significant differences in the TNF-a -308
promoter genotypic distribution between the patients with
CP and healthy controls (table 3).
DISCUSSION
An association between genetic predisposition to high
production of TGF-b1 and the risk of developing chronic
pancreatitis was found in Brazilian, mixed-raced people
[17]. A similar association was suggested by Schneider et
al., who compared the genotypic frequencies of polymor-
phism at position +869 in individuals with alcoholic
chronic pancreatitis and in healthy controls, but they did
not find a statistically significant difference between the
groups. However, they did observe a tendency for indi-
viduals with alcoholic chronic pancreatitis to be homozy-
gous for the T allele [18].
We investigated the frequency of the TT genotype in pa-
tients with chronic pancreatitis, relative to that in healthy
controls, and also compared the genotypes between pa-
tients treated medically and those undergoing surgery. The
latter patients were regarded as a “ severe” group, with
considerable progression of the disease. The differences in
TT genotype frequency proved significant between the
surgical group and the controls, and between the surgical
and the medical group. The frequency of the TT genotype
was relatively high among the medically-treated patients,
but only as a tendency and was without statistical signifi-
cance.
This means that chronic pancreatitis patients, who do not
need surgery, rather carry the “protective” C allele, while
the TT genotype seems to be a risk factor for surgery. It is
noteworthy, that repeat surgery was necessary within three
years in eight patients , all of whom were TT homozygotes.
The highest TGF-b concentrations (5.2-7.4 ng/mL) were
detected in the plasma of these patients. It is notewoethy,
that these patients were heavy drinkers.
The plasma levels of TGF-b1 were significantly increased
among the chronic pancreatic patients overall as compared
with the group of healthy blood donors (3.98 ±1.26 ng/mL
versus 2.1 ± 0.85 ng/mL). Higher concentrations of
TGF-b1 were detected in the plasma of those subjects with
the TT and TC genotypes as compared with those with the
CC genotype, both among the patients and among the
controls (figure 1). The frequency of high producers (TT)
was higher among the patients with chronic pancreatitis
than among the controls (table 1), and the TGF-b1 levels
differed in the patient and control groups (figure 1). It is
tempting to speculate that in the “high producer” patients,
the inflammatory stimuli resulted in elevated levels of
TGF-b1, which further increased the fibrotic processes in
the pancreatic tissue.
The results of other studies support the idea of a role of
TNF in chronic pancreatitis [7, 28]. In our present study,
we could not confirm this result; there was no association
found between TNF-a polymorphism and chronic pancre-
atitis in our studies. One of the possible explanations for
the conflicting findings might be the small size of our
study.Our results are in line however, with the report of
Schneider and colleagues [18, 29] and with Beranek et al.
[30]. In their study, no association between the TNF-a
promoter polymorphism and chronic pancreatitis was
found.
We detected a considerable difference in the IL-8 polymor-
phism between the chronic pancreatitis patients and the
controls. Howell et al. [31] reported a non-significant
decrease in frequency of the IL-8 -251 poymorphism in
patients with chronic pancreatitis as compared to the con-
Table 2
IL-8 -251 genotype distribution in patients with chronic pancreatitis and in control subjects
TT TA AA
Operated 7/40 (17%) 23/40 (58%) 10/40 (25%)
Non operated 6/43 (14%) 25/43 (58%) 12/43 (28%)
ns versus operatedb
Total 13/83 (15%) 48/83 (58%) 22/83 (27%) p = 0.0027a
p = 0.007 versus controlb p = 0.0271 versus controlb
Control 30/75 (40%) 30/75 (40%) 15/75 (20%)
ns = non significant.
a chi-square test versus control.
b Fisher test.
Table 3
TNF-a -308 genotype distribution in patients with chronic pancreatitis and in control subjects
GG GA AA
Operated 24/40 (60%) 13/40 (32%) 3/40 (8%)
Non operated 32/43 (74%) 8/43 (19%) 3/43 (7%)
Total 56/83 (67%) 21/83 (25%) 6/83 (7%) p = 0.417 nsa
Control 52/75 (69%) 21/75 (28%) 2/75 (3.%)
ns = non significant.
a chi-square test versus control.
TGF-b and IL-8 and TNF-a polymorphisms in chronic pancreatitis 35
Co
py
rig
ht
 ©
 2
01
9 
Jo
hn
 L
ib
be
y 
Eu
ro
te
xt
. T
él
éc
ha
rg
é 
pa
r U
NI
VE
RS
IT
Y 
O
F 
SZ
EG
ED
 le
 0
2/
07
/2
01
9.
trols, which was unexpected because others have described
an increased expression of IL-8 in chronic pancreatitis [9].
Our results concerning the association of a higher fre-
quency of the high IL-8-producing genotype (A/T) with
CP is in accordance with the finding of these authors. No
significant difference in frequencies of the IL-8 polmor-
phism was observed however, between the two groups of
patients. Accordingly, we presume that the high IL-8 -
producing phenotype may be a predisposing factor for the
development of inflammatory processes in chronic pancre-
atitis, but this SNP might not be connected with the sever-
ity of the disease.
We earlier observed a correlation between the IL-8 -251
polymorphism and acute pancreatitis [32]. The relation-
ship between acute and chronic pancreatitis has long been
debated. It is currently, generally assumed that the onset of
CP is closely linked with recurrent episodes of acute pan-
creatitis [33]. It is tempting to speculate that a high IL-8-
producing genotype - together with other predisposing
factors (e.g. alcohol consumption) may be a risk factor for
the progression of relapsing alcoholic pancreatitis into
irreversible fibrosis observed in CP.
There was no connection between the IL-8 and TGF-b
SNPs. However, it is noteworthy, that seven of the eight
patients who underwent repeat surgery simultaneously
carried the mutant alleles of IL-8 -251, and were TT
homozygotes for TGF-b +869. We hypothesize that this
observation may possibly be of prognostic value.
In conclusion, it is very likely that both TGF-b1 and IL-8
polymorphisms contribute to the genetic susceptibility to
chronic pancreatitis. The IL-8 -251 polymorphism, with its
high IL-8-producing phenotype may be a risk factor for the
development of chronic pancreatitis, but the presence of
this SNP does not influence the outcome as regards pro-
gression, with the necessity for surgery. In contrast, the
TGF-b1 genetic polymorphism with higher TGF-b1 pro-
duction appeared relevant among those patients with
chronic pancreatitis who underwent surgery, particularly
when repeat surgey was necessary.
As chronic pancreatitis is a multifactorial disease, overpro-
duction of cytokines is an important, but not an absolute
factor in the pathogenesis of the disease. Moreover, ex-
pression of TNF-a and TGF-b1 is complex, and is prob-
ably modified by haplotype, cell type and stimulus, there-
fore care has to be taken not to over-exaggerate the
robustness of the association of SNPs and this disease.
The small number of subjects in our preliminary study is
an indicator of the need for caution. Although there were
significant differences in the TGF-b TT genotype distribu-
tions (table 1) the statistical power of the results was 88%
only in the case of comparison the group of patients overall
(n = 83) with the controls. Following the stratification of
patients to surgical (n = 40) and medically-treated groups
(n = 43), the statistical power was 97%, comparing the
data for controls with the patients who underwent surgery.
However, when the frequency of the TT genotype in the
two groups of patients was compared, the power of statis-
tics was only 66%. For a strong (80%) power, the number
of patients in each group should be increased to 80, which
requires a multicenter approach.
Therefore, our results can be regarded as preliminary re-
sults, drawing attention to the possible prognostic value of
TGF - b1 polymorphisms and the associated TGF-b1
levels in chronic pancreatitis, which should be confirmed
in a future, multicenter study on a larger series of patients.
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